Clinical trial
Isatuximab in Combination With Bortezomib and Lenalidomide With Minimal Dexamethasone in Transplant-ineligible Multiple Myeloma
NCT04939844 is registered in ClinicalTrials.gov with Oslo University Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Isatuximab in Combination With Bortezomib and Lenalidomide With Minimal Dexamethasone in Transplant-ineligible Multiple Myeloma
- Lead sponsor
- Oslo University Hospital
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- June 29, 2021
- Completion date
- August 31, 2024
- Enrollment
- 51 (actual)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.